General Information - malecare.org

PSA Decline is a Potential Biomarker for Identifying Early Resistance to Zytiga and Xtandi In Men Who are Post Chemotherapy*

Abiraterone Acetate (Zytiga) and enzalutamide (Xtandi) are the newest generation hormonal agents. They both have demonstrated a survival advantage in men with castrate resistant prostate cancer (CRPC) who have already been treated with docetaxel (chemotherapy). Unfortunately all men who are responsive to both of these drugs eventually become resistant. Some men are subject to early [...]

By Malecare|2017-10-19T10:48:08-04:00July 9th, 2014|abiraterone acetate, Advanced Prostate Cancer, biomarkers, Drugs & Treatments, enzalutamide, General Information, Uncategorized, Understanding APC, Xtandi, Zytiga|0 Comments

Defaulting Cancer Treatment Is Associated with Psychological Distress and A Desire for Psychological Support*

Sometimes some of us just simply decide that we will not start any treatment or continue a treatment protocol simply because we don’t want to have treatment. This type of decision is different from our deciding that a specific treatment has too many side effects for the potential upside it might provide. Researchers set out [...]

By Malecare|2014-07-08T09:56:48-04:00July 8th, 2014|Advanced Prostate Cancer, Drugs & Treatments, General Information, How We Live, mental health, Research, Uncategorized, Understanding APC|0 Comments

What you Need to Know About Denosumab (Xgeva)

Xgeva is used in men with advanced and metastatic prostate cancer with bone metastases for the prevention of developing additional skeletal-related events (not to be confused with bone mineral density). In a phase 3 trial, the 147 Study, evaluating denosumab (Xgeva) versus placebo 1,432 men with castrate-resistant prostate cancer demonstrated that Xgeva improved median bone [...]

By Malecare|2014-06-19T09:53:16-04:00June 19th, 2014|Advanced Prostate Cancer, bisphosphonates, Bone Metastases, denosumab - Xgeva, Drugs & Treatments, General Information, Uncategorized, Understanding APC, Xgeva|0 Comments

ASCO 2014 – Exercise Cuts Cytokines in Prostate Cancer

Research released at the ASCO meeting in Chicago confirms that regular exercise is a must for men with advanced prostate cancer. It was found that a regular and structured physical exercise program reduces cytokine production which is related to depression and to the inflammatory processes. According to the researchers these factors may impact prostate cancer [...]

By Malecare|2017-10-19T10:48:09-04:00June 6th, 2014|Advanced Prostate Cancer, ASCO, Drugs & Treatments, General Information, Quality of Life, Research, Uncategorized, Understanding APC|0 Comments

NICE Rejects Zytiga for Men Without Chemotherapy Exposure

The National Institute for Health and Care Excellence (NICE), which is Britain’s healthcare cost-effectiveness agency, has determined that abiraterone (Zytiga) was not worth giving to men with castrate resistant metastatic prostate cancer who have yet to had chemotherapy. Unlike the FDA in the United States which rules only on a drug’s efficacy, NICE decides if [...]

By Malecare|2014-05-14T10:53:53-04:00May 14th, 2014|Advanced Prostate Cancer, General Information, NICE, Uncategorized, United Kingdom - England, Northern Ireland, Scotland & Wales, Zytiga|4 Comments